Inari Medical : Presentation August 2022

Investor Presentation

NASDAQ: NARI August 3, 2022

This presentation (together with any other statements or information that we may make in connection therewith) may contain are forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, including any estimates of fourth quarter revenue and total procedures, the potential impact of COVID-19 on the business, total addressable market, future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; our business model and strategic plans for our products, technologies and business, including our implementation thereof; competitive companies and technologies and our industry; the impact on our business, financial condition and results of operation from the ongoing and global COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide; our ability to commercialize, manage and grow our business by expanding our sales and marketing organization and increasing our sales to existing and new customers; third-party payor reimbursement and coverage decisions; commercial success and market acceptance of our products; our ability to accurately forecast customer demand for our products and manage our inventory; our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States; the timing or likelihood of regulatory filings and approvals; our ability to hire and retain key personnel; our ability to obtain additional financing; and our expectations about market trends. Without limiting the foregoing, the words "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words.

Forward-looking statements are based on and reflect management's current expectations, assumptions, estimates and projections that may or may not prove to be correct. These forward-looking statements are subject to a number of known and unknown risks, uncertainties, assumptions and other factors, many of which are beyond our control. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this presentation may not occur and our actual results, results, levels of activity, performance or achievements could differ materially and adversely from those anticipated or implied by any forward-looking statements. These and other known risks, uncertainties and factors are described in detail under the caption "Risk Factors" and elsewhere in our filings with the Securities and Exchange Commission ("SEC"), including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. These filings are available in the Investor Relations section of our website at https://ir.inarimedical.com/ or at www.sec.gov.

The forward-looking statements in this presentation are made only as of the date hereof. Except to the extent required by law, we assume no obligation and do not intend to update any of these forward-looking statements after the date of this presentation or to conform these statements to actual results or revised expectations. All forward-looking statements are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements.

This presentation is not an offer to sell securities of Inari Medical and it is not soliciting offers to buy securities of Inari Medical nor will there be any sales of securities of Inari Medical in any state or jurisdiction where the offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Take Care of Our Patients. Take Care of Our People. Make No Small Plans.

A Mission, A Plan, and Crisp Execution Producing Strong Growth

We are committed to changing lives in the most extraordinary ways. We are committed to our people.

Purpose Built Solutions,	Inari devices are designed to solve specific problems. They are not re-purposed or derived from
Differentiated Devices	other disease states, anatomy, or platforms. Inari devices are highly differentiated.
BIG, Growing, and Efficient	Exited 2021 with over 200 U.S. territories. Continued expansion to at least 275 U.S. territories
Commercial Team	planned by FYE 2022.
Large Markets,	Our core VTE market opportunity is $5.8B in the U.S. alone.1 Inari penetration remains <5%.
Lot of Runway
Data Drives Adoption,	Robust portfolio of high-quality data has already emerged: CLOUT DVT, FLASH PE, FLAME high-
Data is a Differentiator	risk PE, PEERLESS RCT. More than 240 peer reviewed publications.
Robust Product Pipeline	2021: 5 new products launched.2
2022: Further accelerating cadence of product introductions. 2 new products launched YTD.2
Efficient Procedures,	Inari products address high acuity disease states, require limited hospital resource, avoid ICU stay,
Favorable Economics	reduce total length of stay, and produce excellent clinical and economic outcomes.
Unique Culture	A mission more important than business.

____________________

1. Based on third party data and Inari management estimates.
2. As of July 31, 2022. Products launched 2021: Triever20 Curve catheter, FlowTriever2 catheter, FlowStasis, FlowSaver, Triever24 Flex catheter; Products launched 2022: ClotTriever BOLD catheter, Intri24 sheath

Strong Leadership Team to Capitalize on Our Opportunity

Bill Hoffman	Mitch Hill	Drew Hykes	Dr. Tom Tu
Chief Executive Officer	Chief Financial Officer	Chief Operating Officer	Chief Medical Officer

Angela Ahmad	General Counsel
Brian Strauss	SVP Engineering
Eric Khairy	SVP Marketing
Eric Louw	VP Manufacturing
Janet Byk	VP Finance & Accounting
John Borrell	SVP Sales
Justin Crockett	VP Inari Solutions Group
Kevin Strange	VP Strategy & Business Development
Kit Cariquitan	VP Quality Assurance & Reg. Affairs

Norman Nie	VP Information Technology
Paul Koehn	SVP Operations
Randy Hamlin	VP Advanced Development
Shawn Flaherty	VP National Accounts
Shon Chakrabarti	VP & General Manager, Chronic Venous Diseases
Tara Dunn	SVP Clinical Affairs & Market Development
Venkat Tummala	VP Medical Affairs
Victor Tapson	VP Medical Affairs
Vitas Sipelis	VP International